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Abstract
Background: It is now emerging that for vaccines against a range of diseases including influenza, malaria and HIV, the
induction of a humoral response is insufficient and a substantial complementary cell-mediated immune response is
necessary for adequate protection. Furthermore, for some diseases such as tuberculosis, a cellular response seems to be the
sole effector mechanism required for protection. The development of new adjuvants capable of inducing highly complex
immune responses with strong antigen-specific T-cell responses in addition to antibodies is therefore urgently needed.
Methods and Findings: Herein, we describe a cationic adjuvant formulation (CAF01) consisting of DDA as a delivery vehicle
and synthetic mycobacterial cordfactor as immunomodulator. CAF01 primes strong and complex immune responses and
using ovalbumin as a model vaccine antigen in mice, antigen specific cell-mediated- and humoral responses were obtained
at a level clearly above a range of currently used adjuvants (Aluminium, monophosphoryl lipid A, CFA/IFA, Montanide). This
response occurs through Toll-like receptor 2, 3, 4 and 7-independent pathways whereas the response is partly reduced in
MyD88-deficient mice. In three animal models of diseases with markedly different immunological requirement;
Mycobacterium tuberculosis (cell-mediated), Chlamydia trachomatis (cell-mediated/humoral) and malaria (humoral)
immunization with CAF01-based vaccines elicited significant protective immunity against challenge.
Conclusion: CAF01 is potentially a suitable adjuvant for a wide range of diseases including targets requiring both CMI and
humoral immune responses for protection.
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Inrtoduction
Vaccination is one of the most successful and cost-effective
public health interventions with more than 2 million deaths being
prevented due to immunization each year [1]. Today, world-wide
campaigns include vaccinations against polio, diphtheria, pertussis
and tetanus and in the last two decades new vaccines have reached
the global market e.g. the vaccine against Haemophilus influenzae
type b. However, a number of widespread and serious diseases
have so far escaped vaccination attempts. International health
priorities such as HIV, TB and malaria are included among the
targets but also the threat of new emerging flu pandemics has
received global awareness and is a highly active area of vaccine
research.
Generally, the main focus for vaccine research has been antigen
discovery whereas the method for inducing immune responses
against these antigens has received relative limited attention.
Therefore, today one of the major obstacles in developing next
generation vaccines is the need for effective adjuvants available for
clinical trials. The paucity of adjuvants is reflected by the fact that
aluminium compounds identified as having immunostimulatory
properties more than 70 years ago remain the only type of
adjuvant licensed for world-wide usage. In addition, the oil-in-
water formulation designated MF59 has received licensure in some
countries as part of an influenza vaccine along with virosomes used
in both influenza and hepatitis A vaccines [2,3]. However, both of
these adjuvants are characterised by inducing humoral immune
responses and are thus effective in elevating serum antibody titers
whereas their ability to elicit cell-mediated immune (CMI)
responses is limited. As many of the remaining difficult disease
targets rely on varying levels of CMI responses with or without an
associated humoral response there is a large unmet need for novel
CMI inducing adjuvants. TB and HIV both belong to this
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a strong CMI response for protection but also many of the existing
vaccines may benefit from an improved adjuvant technology that
would stimulate both arms of the immune system. This is
illustrated by influenza where antibodies neutralize the infectivity
of the virus and the cytotoxic T-cells reduce viral spread and
thereby serve to enhance the recovery from influenza [4].
Herein, we evaluated the immunogenicity and efficacy of a
newly developed liposomal adjuvant, designated cationic adju-
vant formulation (CAF01) [5]. This adjuvant is based on
liposomes formed by N,N9-dimethyl-N,N9-dioctadecylammo-
nium (DDA) with the synthetic mycobacterial immunomodulator
a,a9-trehalose 6,69-dibeheneate (TDB) inserted into the lipid
bilayers. We demonstrate that compared to a panel of
commercially available adjuvants, CAF01 was particular effec-
tive in generating strong cellular immune responses and in
addition hereto a strong antibody response with high titers of
IgG2. Experiments using TLR2, 3, 4, 7 gene-deficient mice
exhibited no defects in this response whereas a reduction was
observed in MyD88 knock-out mice. In three animal disease
models with markedly different immunological requirement;
Mycobacterium tuberculosis (CMI), Chlamydia trachomatis (CMI/
humoral) and blood-stage malaria (humoral), immunization with
selected candidate vaccine antigens administered in CAF01 gave
rise to significant levels of protection.
Materials and Methods
Animals
Six- to 10-week-old female BABL/c, C57BL/6 mice were
purchased from Harlan Scandinavia. Breeding pairs for mice
deficient in MyD88 and TLR 3, 4 and 7 were kindly provided by
Dr. S. Akira (Osaka, Japan). TLR2, TLR3, TLR4 and TLR7
knockout mice were backcrossed onto a C57BL/6 background to
obtain TLR2, TLR3, TLR4 and TLR7 quadruple-deficient mice.
All mice were backcrossed for at least six generations to C57BL/6,
before TLR-deficient mice were successively interbred to generate
mice homozygous for the knockout allele in the loci for TLR2,
TLR3, TLR4 and TLR7. Mice receiving a mycobacterial
challenge were housed in a BSL-3 facility. All experiments were
conducted in accordance with the regulations set forward by the
Danish Ministry of Justice and Animal Protection Committees and
in compliance with EC Directive 86/609.
Reagents
Aluminium hydroxide (Al(OH)3) (2% alhydrogel) was from
Brenntag Biosector (Frederikssund, Denmark), monophosphoryl
lipid A from Avanti Polar Lipids (Alabaster, AL), Montanide
ISA720 from Seppic (France), and Complete Freunds Adjuvant
(CFA) and Incomplete Freunds Adjuvant (IFA) from Statens
Serum Institut (Copenhagen, Denmark). Dimethyldioctadecylam-
monium (DDA) bromide and a,a9-trehalose 6,69-dibehenate
(TDB) were purchased from Avanti Polar Lipids and a stable
formulation designated CAF01 prepared by the lipid film
hydration method as previously described [5].
Antigens
Ovalbumin (OVA) was obtained from Sigma. OVA CD4 T cell
epitope (ISQAVHAAHAEINEAGR) and CD8 T cell epitope
(SIINFEKL) were purchased through Schafer-N (Copenhagen,
Denmark). The fusion protein of Ag85B and ESAT-6 was
produced as a recombinant protein as previously described [6]
and the major outer membrane protein (MOMP) from Chlamydia
muridarum was expressed in the pDest17 system (Gateway,
Invitrogen) and purified as described [7]. The 19kDa C-terminal
protective fragment of MSP1 [8] was amplified from Plasmodium
yoelii genomic DNA using the PYMSP1_fw (59-CAC CGG CAC
ATA GCC TCA ATA GCT TTA AAC A) and PYMSP1_rev (59-
CTA GCT GGA AGA ACT ACA GAA TAC ACC TT) primers.
Amplification was carried out for 25 cycles with denaturation at
94uC for 30 sec, annealing at 55uC for 30 sec, and extension at
72uC for 2 min, using Phusion polymerase (Finnzymes, Espoo,
Finland). The resulting DNA fragment was cloned into pENTR/
D-TOPO (Invitrogen, Copenhagen) and subsequently into
pDEST17 expression vector. The corresponding recombinant
protein was purified by metal chelate affinity chromatography
essentially as described [9].
Immunization
Mice were immunized three times at 2-week intervals
subcutaneously (s.c.) at the base of the tail using a volume of
200 ml. Alternatively, mice were injected twice at 2-week intervals
in the footpad with a volume of 50 ml. All mice received a dose of
250 mg DDA/50 mg TDB or 500 mg of Al(OH)3 with either 100 mg
of OVA, 2 mg of Ag85B-ESAT-6, 5 mg of MOMP or 10 mgo f
MSP1-19. OVA was also administered in combination with 250
mg of DDA, 70 ml Montanide/dose, or CFA followed by two
boosts with IFA. A homogenous preparation of Montanide/OVA
was prepared by using a micro-emulsifying needle (Fischer
Scientific, US) [10]. DDA liposomes were prepared as previously
described [11]. The experimental protocol for the three disease
model has been depicted in Fig. 1.
Detection of vaccine-specific antibodies by ELISA
Micro titers plates (Nunc Maxisorp, Roskilde, Denmark) were
coated with OVA (2 mg/ml), Ag85B-ESAT-6, MOMP, or
MSP1-19 (all 0.5 mg/well) in PBS overnight at 4uC. Free binding
sites were blocked with 2% skim milk in PBS. Individual mouse
serum from three to six mice per group was analysed in duplicate
in fivefold dilutions at least 8 times in PBS containing bovine
serum albumin starting with a 20-fold dilution. Horseradish
peroxidase (HRP)-conjugated secondary antibodies (rabbit anti-
mouse immunoglobulin G1; IgG1 and IgG2a/b/c; Zymed)
diluted 1/2000 in PBS with 1% bovine serum albumin was
added. After 1 h of incubation, antigen-specific antibodies were
detected by TMB substrate as described by the manufacturer
(Kem-En-Tec, Copenhagen, Denmark). The absorbance values
were plotted as a function of the reciprocal dilution of serum
samples. Reciprocal plasma dilutions corresponding to 50%
maximal binding (i.e EC50) were computed using the Prism
software (v. 4.00; GraphPad Software Inc.). In BALB/c mice, the
IgG2a isotypes was measured whereas IgG2b and c levels were
analyzed in C57BL/6 mice as the gene for IgG2a is deleted in
this strain [12].
Lymphocyte cultures
Cultures of inguinal lymph nodes or spleens were obtained by
homogenizing the organ into complete RPMI (RPMI 1640
supplemented with 5610-5 M 2-mercapthoethanol, 1 mM
glutamine, 1% penicillin-streptomycin, 1% HEPES and 10%
fetal calf serum all from Gibco (Invitrogen, Carlsbad, CA) and
subsequently washed twice and adjusted to a final concentration
of 2610
5 cells/well in a total volume of 200 ml/well. Antigens
were used at different concentrations (ranging from 0.05 to 10
mg/ml), whereas Con A was used at a concentration of 1 mg/ml
as a positive control for cell viability. Culture supernatants were
harvested from parallel cultures after 72 h of incubation for the
CAF01
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described [13].
IFN-c ELISPOT
96-well PVDF filter microtiters plates (MAHA S45 10 Millipore
Corp, MA) were coated over-night with 4 mg/ml IFN-c capture
Ab (Pharmingen, San Diego, CA) in PBS. Plates were washed five
times and blocked with RPMI medium containing 10 % FCS.
Splenocytes from individual mice were added in duplicates and
incubated for 48 h at 37uC, 5% CO2 with 5 mg of OVA. Plates
were subsequently washed with 0.05% Tween in PBS and
incubated with 1.25 mg/ml of anti-IFN-c-biotin secondary Ab
diluted in PBS (Clone XMG1.2; BD Pharmingen) for 2 h and
phopsphatase-conjugated streptavidin (Jackson Immunoresearch
Laboratories) for 45 min. The enzyme reaction was developed
with 5-bromo-4-chloro-3indolylphosphate (Sigma Aldrich). Spots
were counted using an automated ELISPOT Reader System and
software (AID, Strassberg, Germany).
Mycobacterial challenge
Mycobacterium tuberculosis Erdman were grown at 37 C in Sauton
medium enriched with 0.5% glucose, 0.5 sodium pyruvate and
0.05% Tween 80. Ten weeks after the first immunization, mice
were infected by the aerosol route using a Glas-Col Inhalation
Exposure System (Glas-Col, Terre Haute, IN) calibrated to deliver
approximately 25 colony-forming units (CFU) of M. tuberculosis into
the airways. At different time points after infection, mice were
sacrificed and organs homogenized in PBS for bacterial enumer-
ation. Individual organs were plated in serial dilutions onto
Middlebrook 7H11 agar supplemented with 2 mg of 2-thiophene-
carboxylic acid hydrazide per ml to selectively inhibits the growth
of BCG. The plates were incubated for 2–3 weeks at 37uC after
which the number of CFUs were counted.
Malaria challenge
Plasmodium yoelii 17XNL clone 1.1 was obtained from Pierre
Druilhe, Institut Pasteur France and propagated in BALB/c mice.
Parasitized red blood cells were kept at 280uC until use.
Challenge infections were performed by intra-peritoneal injection
of 10
5 parasitized red blood cells. The course of the infection was
monitored by microscopic examination of thin blood smears. P.
yoelii infected cells were washed three times with PBS before
making the smears.
Chlamydia challenge
The C. muridarum strain MoPn/NiggII was purchased from the
American Type Culture Collection (ATCC, Manassas, VA, USA)
and propagated in HeLa-229 cells as described [14]. Chlamydia
elementary bodies were harvested, purified and quantified [15]
and stored at 280uC in a sucrose-phosphate-glutamate (SPG)
buffer. Female C57BL/6 mice were used for vaccine experiments.
One week before C. muridarum challenge, the mice oestrus cycle
was synchronized by subcutaneous injection of 2.5 mg Medrox-
yprogesteronacetat (Depo-Provera; Pfizer, Ballerup, Denmark).
Six weeks after the final vaccination, the mice were challenged
intra-vaginally with 1.5610
5 inclusion forming units (IFU)
(determined as 1006ID50)o fC. muridarum in 10 ml SPG buffer.
Vaginal swabs were obtained at 3, 7, 10, 14 and 21 days after
infection. Swabs were vortexed with glass-beads in 1 ml SPG
buffer and stored at 280uC until analysis. Infectious load was
assessed by infection of McCoy cell monolayers with a titrated
volume of the swap suspension essentially as described previously
(16). Fourty hours after infection, McCoy cells were fixed and
chlamydia inclusions stained with a polyclonal rabbit anti-MOMP
serum, followed by a FITC conjugated swine anti-rabbit Ig
(DAKO). Background staining was done with propidium iodide
(Invitrogen). Swap titrations were done in duplicate. Inclusions
were enumerated by visual inspection using a fluorescence
microscopy.
Statistical analyses
For analyzes of immune responses and vaccine efficacy, data
were tested by analyzes of variance (more than two groups) or a t-
test (two groups). When significant differences were indicated,
differences between means were determined by Dunnett’s multiple
comparison test.
Results
Vaccination with CAF01 gives rise to the induction of
both cell-mediated and humoral immune responses
The ability of CAF01 to induce both humoral and cell-
mediated immune responses was analyzed using a model antigen
OVA and the responses compared to other adjuvants; Montanide,
MPL, DDA, Freunds complete/incomplete (CFA/IFA) adjuvant
and including aluminium hydroxide (Al(OH)3) which is licensed
for human use. C57BL/6 mice were immunized three times with
Figure 1. Time schedule for the immunization and infection regimen for TB, chlamydia and malaria.
doi:10.1371/journal.pone.0003116.g001
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antibody responses as well as T-cell responses was measured by
ELISA and ELISPOT, respectively, one week after the last
immunization. Fig. 2A demonstrates that CAF01 promoted CMI
responses with frequencies of IFN-c positive cells ranging from 1/
4000 to1/5000. This response was primarily directed against the
CD4 T cell epitope in OVA (ISQAVHAAHAEINEAGR) (Fig. 2B)
whereas the response to the CD8 T cell epitope (SIINFEKL) was
at lower levels (Fig. 2C). OVA administered in MPL and DDA
also induced significant number of Ag-specific cells but at lower
levels compared to CAF01. In MPL-immunized mice this response
was primarily seen upon stimulation with the CD8 T cell epitope.
In addition, CAF01 induced OVA-specific IgG1 antibody titers
comparable to CFA/IFA, which is the classical immunization
regimen for antibody induction in mice, (Fig. 2D) whereas all other
adjuvants showed lower levels of humoral responses. In general,
the level of IgG2b (Fig. 2E) and IgG2c (Fig. 2F) antibodies was
lower compared to IgG1 titers but CAF01 as well as Montanide
and CFA/IFA gave rise to detectable levels of these isotypes. Mice
receiving OVA alone failed to exhibit an antibody response (results
not shown).
High levels of protection against three diseases with
markedly different immunological requirements using
CAF01-based vaccines
The ability of CAF01-based vaccines to elicit protection against
three different diseases with markedly diverse requirements in
terms of balance between CMI and humoral responses was
evaluated. Protection against asexual blood-stage malaria is
considered to be mediated primarily by antibodies whereas the
induction of potent Th1-directed T cell responses is known to be
vital in controlling a TB infection. Immunity against chlamydia for
comparison relies on the combined action of CMI and humoral
responses. For all three diseases, leading antigen vaccine
candidates were selected among antigens with a proven track
record and used to assess the adjuvant efficacy of CAF01. The
antigens were the Plasmodium yoelii MSP1-19 antigen (C-terminal
19-kDa processing fragment of MSP1) which is already in clinical
trials with different adjuvants [17,18], the Ag85B-ESAT-6 fusion
antigen of Mycobacterium tuberculosis which recently went through a
phase Ia trial and now has entered a phase Ib trial [19] and the
well-established chlamydia vaccine antigen MOMP [20,21]. A
standard immunization scheme was used for all three diseases
involving three subcutaneous vaccinations administered with a
two-week interval followed by a rest-period between three to six
weeks before administration of a virulent challenge administered
as outlined in Fig. 1. The immunogenicity was evaluated one week
and three weeks after the final vaccination by monitoring the levels
of vaccine-specific antibodies in the sera and by evaluating the
IFN-c recall response to the vaccine antigen in splenocyte cultures.
For all three antigens the responses were compared to Al(OH)3
adjuvanted preparations as this adjuvant is presently the most
widely used adjuvant in human vaccines.
M. tuberculosis: The mycobacterial fusion protein Ag85B-ESAT-
6 in CAF01 induced strong humoral responses with titers of
Ag85B-ESAT-6 specific IgG1 antibodies reaching 35,000 which
was the same level obtained with the Al(OH)3-adjuvanted vaccine
(Fig. 3A). The IgG2b (Fig. 3B) and c (Fig. 3C) titers induced by the
CAF01 adjuvanted vaccine for comparison was significantly
Figure 2. Comparison of CAF01 with other adjuvants. C57BL/6 mice (n=4) were immunized three times with 100 mg of OVA in CAF01,
Al(OH)3, Montanide, MPL, CFA/26IFA boosting with a two-week interval. A) Three weeks after the last immunization, the number of OVA-specific cells
was assessed by IFN-c ELISPOT. Mean spot-forming units (SFU) upon stimulation with 5 mg of OVA per million cells 6 SEM for each group is shown. B)
SFU per million cells 6 SEM upon stimulation with 5 mg of OVA CD4 T cell epitope. C) SFU per million cells 6 SEM upon stimulation with 5 mg of OVA
CD4 T cell epitope. D) Sera were analysed for the presence of OVA-specific IgG1, E) IgG2b, F) IgG2c antibodies by ELISA. Mean EC50 6 SEM is shown.
Values marked with an asterisk are significantly different (*, p,0.05; **, p,0.01, p,0.001) compared to naı ¨ve controls as assessed by ANOVA and
Dunnett’s multiple comparison test.
doi:10.1371/journal.pone.0003116.g002
CAF01
PLoS ONE | www.plosone.org 4 September 2008 | Volume 3 | Issue 9 | e3116Figure 3. Immune responses and protection induced by CAF01 in a TB model. C57BL/6 mice were immunized three times with 2 mgo f
Ag85B-ESAT-6 in CAF01 or Al(OH)3. A) Three weeks after the last immunization, mice were bled by periorbital puncture and individual sera tested for
Ag85B-ESAT-6 IgG1, B) IgG2b or C) IgG2c by ELISA (n=6). D) Individual cultures of splenocytes (n=3) were harvested at the same time point and re-
stimulated in vitro with different concentrations of the Ag85B-ESAT-6. The release of IFN-c was determined by ELISA. Six weeks after the last
immunization, mice were challenged by the aerosol route with virulent M. tuberculosis. Six weeks postchallenge, mice were sacrificed and the
bacterial burden (CFU) measured in the E) lungs or F) spleen (expressed as log10 CFU). As a positive control group, a group of mice received a BCG
vaccination ten weeks before challenge. Data shown are mean values of six mice 6 SEM. G) At different time points after infection, mice were
sacrificed and the CFU measured in the lungs. Values marked with an asterisk are significantly different (*, p,0.05; **, p,0.01, p,0.001) compared to
naı ¨ve controls as assessed by ANOVA and Dunnett’s multiple comparison test.
doi:10.1371/journal.pone.0003116.g003
CAF01
PLoS ONE | www.plosone.org 5 September 2008 | Volume 3 | Issue 9 | e3116higher than the Al(OH)3-promoted responses. No detectable levels
of antibodies were seen in mice receiving CAF01 without antigen
or in un-vaccinated animals. Ag85B-ESAT-6 in CAF01 was also
highly immunogenic when assessing cell-mediated immune
responses with levels of more than 20,000 pg/ml IFN-c released
to the supernatant after restimulation of splenocytes with Ag85B-
ESAT-6 (Fig. 3D). The IFN-c response was found to be mediated
primarily by CD4+ T cells as restimulation with either the intact
Ag85B-ESAT-6 fusion protein or peptides spanning the two proteins
followed by intracellular cytokine staining and FACS analysis
identified a higher percentage (2–4%) of IFN-c positive among the
CD4+ T cell compared to the CD8+ Tc e l lp o p u l a t i o n( 0 . 3 % )( r e s u l t s
not shown). Subsequently, the Ag85B-ESAT-6/CAF01, the Ag85B-
ESAT-6/Al(OH)3 as well as the CAF01 adjuvant control and BCG
vaccinated mice were challenged through the aerosol route with M.
tuberculosis Erdman. Ag85B-ESAT-6 in CAF01 provided significant
levels of protection (p,0.001 and p,0.01 for lungs and spleen,
respectively) comparable to that offered by the standard BCG
vaccination (Fig. 3E and F). The adjuvant control did not give rise to
any non-specific immunity against the TB challenge. As expected,
Ag85B-ESAT-6 delivered in Al(OH)3 gave rise to low levels of cell-
mediated immune responses and failed to provide protection against
TB. In order to assess the duration of the CAF01-induced protection,
bacterial growth was monitored at different timepoints (week 4, 6, 12
and 24 after infection) after infection showing the maintenance of
approximatelyone log reduction in bacterial numbersthroughout the
course of infection at a level almost comparable to that seen in mice
receiving the live BCG vaccine (Fig. 3G).
To further study the mechanism of this adjuvant effect of
CAF01, we evaluated whether the response was dependent on the
MyD88 signalling pathway which is the common TLR-signalling
adaptor molecule or dependent on different TLRs including
TLR2 and TLR4 known to have a role in the recognition of
mycobacterial lipid components. MyD88 deficient mice as well as
mice with gene deficiencies in TLR2, 3, 4 and 7 was vaccinated
twice with Ag85B-ESAT-6 in CAF01 and the cellular immune
response analyzed in the inguinal lymph nodes two weeks after
vaccination. As shown in figure 4B, prominent levels of IFN-c was
seen in the TLR2, 3, 4 – and 7 quadruple knock-out mice at a
level comparable to what was obtained in wild type animals. In
contrast, a significant decrease was observed in MyD88 gene
deficient mice (Fig. 4A).
Malaria: Very high levels of MSP1-19 specific IgG1 and IgG2a
antibodies were induced with between 10 (IgG2a) and 700 (IgG1)
fold higher levels in the CAF01 adjuvanted MSP1-19 group as
compared to the Al(OH)3 adjuvanted group (p,0.01 for both
IgG1 and IgG2a) (Fig. 5A and B). In general, the level of cell-
mediated response measured as antigen specific IFN-c release after
in vitro re-stimulation with MSP1-19 was lower compared to the
Ag85B-ESAT-6 responses obtained but again CAF01 vaccination
led to 5–8 times higher response compared to Al(OH)3 adjuvanted
MSP1-19 (Fig. 5C). No responses were seen in mice receiving
MSP1-19 without adjuvant or in un-vaccinated animals. Vacci-
nated mice received a non-lethal Plasmodium yoelii infection through
the intraperitoneal route. In the CAF01 group, peak parasitemia
occurred around day 10 post challenge with a mean of 35% 6 2.5
after which a clearance of parasites from the circulation was seen
with no detectable infected erythrocytes from day 15 and onwards
(Fig. 5D). In the Al(OH)3 adjuvanted MSP1-19 group a much
more protracted course of infection was observed; clearance
occurred at a later time point and was not complete even at day
22. In a second experiment, the protection conferred by MSP1-19
in CAF01 was compared to non-vaccinated animals showing
significant protection in CAF01-immunized mice from day 4 and
onto day 12 (Fig. 5E).
Chlamydia trachomatis: Upon vaccination with the chlamydia
antigen MOMP, the same level of IgG1 titers was seen in the
CAF01 and Al(OH)3 groups (Fig. 6A). In agreement with the
results obtained with the other antigens described above, MOMP
in CAF01 led to significantly higher levels of IgG2b and IgG2c
(app. 200 fold) compared to MOMP/Al(OH)3 (p,0.01 and 0.001,
respectively) (Fig. 6B and C). Consistent with this antibody isotype
distribution, the antigen specific IFN-c recall response was also
significantly elevated in the MOMP/CAF01 group (Fig. 6D). As in
the TB model, the CAF01-based vaccine primarily induced a CD4
T cell response (results not shown). No responses were observed in
mice receiving CAF01 alone or un-vaccinated control mice. The
vaccine-induced protection in MOMP/CAF01 and MOMP/
Al(OH)3 was assessed by the administration of a vaginal challenge
with Chlamydia muridarum. The course of infection was followed by
enumeration of the number of bacteria in vaginal swabs taken at
various time points during infection. Mice that had been
vaccinated with MOMP in CAF01 were partially protected and
exhibited decreased bacterial load at all time points post infection
compared to both un-vaccinated control animals and mice
receiving MOMP delivered in Al(OH)3 (Fig. 6E). The clearance
of bacteria in the Al(OH)3 adjuvanted vaccine was identical to that
of with naı ¨ve controls. In addition, the CAF01-based chlamydia
Figure 4. CAF01-induced responses in TLR2, 3, 4, 7 and MyD88-deficient mice. A) MyD88-/- and B) TLR2, 3, 4, 7-/- mice as well as WT
controls mice (n=3) were vaccinated twice with 2 mg of Ag85B-ESAT-6 in CAF01 by footpad immunization. Two weeks after the last immunization,
the inguinal lymphnodes were harvested and restimulated in vitro with 10 mg of Ag85B-ESAT-6. The release of IFN-c was determined by ELISA.
doi:10.1371/journal.pone.0003116.g004
CAF01
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and 5/15 being culture negative already on day 4 and 7 post
infection (results not shown). At these time points there was no
reduction in the number of culture positive mice in either un-
vaccinated control animals or in animals receiving MOMP in
Al(OH)3.
Discussion
It is becoming increasingly clear that for peptide- or protein
subunit vaccines, amplification of T cell priming through the fine
tuned combination of antigen uptake and dendritic cell (DC)
activation is necessary to elicit optimal protective immune
responses for a large range of diseases. CAF01 is a two-component
adjuvant system that consists of an immunomodulator (TDB) and
a cationic liposome (DDA) that act in synergy to enhance vaccine-
specific immune responses. In this regard, CAF01 share
similarities with some of the new promising adjuvant systems that
have recently been developed. This includes the GSK series of
adjuvants focused on combining immunomodulators like MPL
and QS21 with different delivery vehicles e.g. conventional
aluminium hydroxide and oil in water emulsions [22]. Others
have encapsulated MPL in PLG microparticles [23], CpG in
liposomes [24], or ODN1a in cationic peptide based particles [25].
Administered alone the vaccine delivery systems in general induce
weak immune responses (as illustrated by DDA alone in Fig. 2) but
in combination with an immunomodulator e.g. a TLR agonist a
synergistic effect is obtained leading to highly potent and
multifaceted immune responses often with both T and B cell
responses (reviewed in [26]). In these adjuvant systems, the
delivery vesicle serves to promote uptake and presentation of the
vaccine antigen in the relevant subset of antigen-presenting cells
(APC), whereas the immunomodulator activate the APC through
interaction with TLR or non-TLR receptors. This synergy has also
been clearly demonstrated for CAF01 where DDA target vaccine
antigen to APCs and TDB provides the proinflammatory response
Figure 5. Immune responses and protection induced by CAF01 in a malaria blood-stage model. BALB/c mice were immunized three
times with 10 mg of MSP1 in CAF01 or Al(OH)3. One week after the last immunization, mice were bled by periorbital puncture and individual sera
tested for MSP1-specific A) IgG1 or B) IgG2a by ELISA (n=5). C) Individual cultures of splenocytes (n=3) were harvested at the same time point and
re-stimulated in vitro with different concentrations of MSP1. The release of IFN-c was determined by ELISA. D and E) Three weeks after the last
immunization, mice were challenged by the i.p. route with Plasmodium yoelli and the number of infected red blood cells measured at various time
points during infection. Data shown are mean values of five mice 6 SEM. Values marked with an asterisk are significantly different (*, p,0.05; **,
p,0.01, p,0.001) compared to Al(OH)3-vaccinated as assessed by t-test.
doi:10.1371/journal.pone.0003116.g005
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OVA onto DDA led to a highly accelerated uptake of antigen by
the DCs in vitro whereas a neglible uptake was seen with OVA
alone [28].
In addition to the synergistic effect on the immune response,
another major benefit of co-formulating antigen and immuno-
modulators into a delivery vehicle is to limit the distribution of the
immunostimulatory components and thereby minimize systemic
toxicity. This ability of liposomes to target preferentially distinct
cells or tissues has been widely used in drug delivery e.g. with
DoxilH for cancer therapy [29]. Recently, the same ability was
demonstrated for the novel adjuvant system IC31 which is highly
effective in promoting cell-mediated immune responses [30]. By
following the fate of fluorescently labelled IC31 upon s.c.
administration in mice only a minute proportion of the DC
population (less than 0.2% of the CD11c+ cells) was found to be
taking up the adjuvant. However, these IC31+ DCs were all highly
activated with increased levels of CD40, CD80 and CD86
expression. Preliminary observations suggest that CAF01 also
elicits a highly targeted and exquisite activation of a minor
proportion of the CD11c+ cells (Kamath, manuscript in
preparation). In contrast, parenteral administration of soluble
CpG leads to a global activation of dendritic cells [30] and highly
elevated systemic levels of IL-6, IL-12 and TNF-a with the
subsequent risk of serious side effects [31,32,33]. Although TDB
and its natural analogue trehalosedimycolate (mycobacterial cord
factor) has been identified as highly active immunomodulators
leading to secretion of IL-1b, IL-6 and TNF-a [34], CAF01 does
not have a systemic effect upon injection in mice (levels of IL-6 and
TNF-a in sera two hours after injection) and was not pyrogenic in
the conventional rabbit pyrogenecity test (results not shown).
TB vaccine development and evaluation has been ongoing for
many years and before the detailed knowledge on antigen delivery
and DC activation was available, vaccine optimization was
performed in an empirical way. It is therefore striking that the
three lead adjuvants for TB subunit vaccines AS01 (Mtb72F) [35],
IC31 (Ag85B-ESAT-6 and Ag85B-TB10.4) [36,37] and CAF01 all
share the same basic combination of a delivery vehicle and a Th1-
Figure 6. Immune responses and protection induced by CAF01 in a chlamydia model. C57BL/6 mice were immunized three times with 5
mg of MOMP in CAF01 or Al(OH)3. Three weeks after the last immunization, mice were bled by periorbital puncture and individual sera tested for
MOMP A) IgG1, B) IgG2b and C) IgG2c by ELISA (n=6). D) Individual cultures of splenocytes (n=3–6) were harvested at the same time point and re-
stimulated in vitro with 5 mg of MOMP. The release of IFN-c was determined by ELISA. E) Six weeks after the last immunization, mice were
administered a vaginal challenge with 1.5610
5 Chlamydia muridarum IFU/mouse and the bacterial load in the vagina monitored at day 4, 7, 10, 14
and 21. Data shown are mean values of 6–7 mice 6 SEM. Values marked with an asterisk are significantly different (*, p,0.05; **, p,0.01, p,0.001)
compared to naı ¨ve controls as assessed by ANOVA and Dunnetts post test.
doi:10.1371/journal.pone.0003116.g006
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like CpG [38] or MPL [39] as well as delivery vehicles administered
without immunomodulators e.g. liposomes or niosomes [40] do not
confer significant protection against TB infection.
In chlamydia research, the lack of effective adjuvants has indeed
been one of the major impediments for the development of an
effective vaccine. Animal challenge experiments showed that
parenteral administration of MOMP in either MF59 [41] or
aluminium hydroxide (Fig. 6, and [42]) provide limited protection
against infection whereas strong CMI responses and efficient
protection was promoted by MOMP adjuvanted with a two-
component adjuvant (Montanide with CpG) [41].
Whereas the data obtained in both the TB and chlamydia
models can be explained by the importance of the CMI responses
promoted by CAF01, a similar explanation appears unlikely for
blood stage malaria where immunity is most likely exclusively
mediated by antibodies [43]. Although the superior protection
provided by CAF01 can simply be explained by larger number of
antibodies, an additional advantage of CAF01 could be the
pronounced Th1-skewed antibody profile with high levels of IgG2
titers. This specific subclass profile is a very consistent observation
in all three models and has been associated with the most potent
proinflammatory and effective antibody response. In agreement,
vaccine-induced IgG2 was previously found particular effective at
mediating immunity to blood stage malaria infection in mouse
models [44]. Although it is not possible to identify a human
analogue, IgG3 shares many characteristics with mouse IgG2
including a more effective anti-malaria response. In epidemiolog-
ical studies carried out in high endemic areas, the level of IgG3 has
been shown to correlate with resistance against the development of
clinical malaria [45]. The higher activity of IgG2 has also attracted
a lot of interest in other fields including chlamydia where this
isotype is found responsible for antibody enhancement of Th1
activation and the subsequent protection [46]. Over the last 5
years, there has been a breakthrough in our understanding of how
the various antibody isotypes interact with either activatory or
inhibitory Fc receptors and thereby mediate the differential
activity observed in vivo [47]. Thus, IgG1 antibodies selectively
binds to inhibitory FccRIIB expressed on dendritic cells whereas
IgG2a and IgG2b antibodies preferentially engage the activatory
Fcc:RIV receptor crucial for the higher in vivo activity observed as
e.g. enhanced phagocytosis and release of inflammatory mediators
[48]. There is therefore a growing interest for the quality of the
vaccine-induced antibody response shown to be of crucial
importance for the development of the cellular immune response
and thereby the protective properties of the vaccine.
Although effective in generating protective B and T-cell
responses, a weakness of nonreplicating vaccine adjuvants
including CAF01 described herein is the limited CD8 T cell
induction against protein antigens. ESAT-615–29 specific CD8 T
cell responses can be induced using an adenovirus vector
expressing the fusion of Ag85B and ESAT-6 [49], however the
CAF01-protein vaccine fails to induce a CD8 T cell response
against the same epitope (results not shown). In addition,
immunization with OVA/CAF01 led to a strong CD4 T cell
response whereas the CD8 T cell response was at lower levels e.g.
in comparison to MPL (Fig. 2B and C). However, recently it was
shown that by administering type I IFN-inducing TLR ligands e.g.
MPL or Poly IC in combination with cationic liposomes a strong
CD8 T cell response to protein antigens can be elicited [50]. This
has also been demonstrated in human trials where vaccination
with a recombinant tumor antigen in CpG/Montanide oil led to
CD8 T cell response in a considerable fraction of the patients [51].
The ability of this type of formulation to cross-prime CD8
responses in vivo has primarily been attributed to the delivery
vehicle mediating efficient interaction between the TLR agonists
and their intracellular receptor thereby promoting immune
activation [52]. The enrichment of CAF01 with different type I
IFN-inducing TLRs is currently under evaluation.
Beyond doubt TLRs have over the last decade become hot
targets for vaccine research with the majority of novel adjuvant
technologies being based on TLR agonists. To study the role of
TLRs in the CAF01-induced immune responses, we vaccinated
mice with gene deficiencies in TLR2, 3, 4 and 7 but failed to
demonstrate a reduction in vaccine-induced IFN-c. In contrast,
the response in MyD88-/- knock-out mice was reduced indicating
that signaling occurs through a different TLR than TLR2, 3, 4, 7.
Alternatively, the signaling could occur through a TLR-indepen-
dent pathway e.g. through the IL1/IL18 receptors known also to
utilize the MyD88 signaling pathway or through an yet
unidentified receptor upstream of MyD88. Indeed, it has also
recently become clear that many classical adjuvants including
FCA are capable of inducing an adaptive immune response in the
absence of TLR-signalling [53,54] and therefore CAF01 may be
included in this group of adjuvants signaling through TLR-
independent pathways.
Our study demonstrates that CAF01 is a very versatile adjuvant
system inducing simultaneously a CMI response and an antibody
response with high levels of IgG2 antibodies. In the clinical
development of liposome-based systems, stability, manufacturing
and quality assurance have been major obstacles. However, in
addition to the synergy in enhancing immune responses, TDB also
has a stabilizing effect on DDA liposomes and the result is a
formulation that maintains the same particle size distribution for
more than 1K years at 4uC ([5] and personal communication:
Lars Vibe Andreasen). This preparation is currently scheduled to
enter clinical trials together with the TB vaccine candidate Ag85B-
ESAT6.
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